<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467269</url>
  </required_header>
  <id_info>
    <org_study_id>BRUSH SIGN</org_study_id>
    <nct_id>NCT03467269</nct_id>
  </id_info>
  <brief_title>BRUSH Sign: Radiolographic Marker of Cerebral Infarctus Prognosis</brief_title>
  <official_title>BRUSH Sign: Radiolographic Marker of Cerebral Infarctus Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Today the treatment of ischemic stroke in acute phase is based on medicinal or endovascular
      revascularization. Cerebral MRI sequences help the diagnostic. This procedure uses
      deoxyhemoglobin as an endogenous tracer. This is also a scorer of cerebral ischemia and the
      increase lets visualized transcerebral veins in the suffering zone giving a brush aspect.
      Several studies show the interest of this sign and conclude that deoxyhemoglobin presence is
      a predictive factor of cerebral ischemia. The aim of the study is to evaluate this brush-sign
      and correlate it with the prognosis retrospectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">April 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>autonomy level</measure>
    <time_frame>Month 3</time_frame>
    <description>measurement of autonomy level by mRS</description>
  </primary_outcome>
  <enrollment type="Actual">250</enrollment>
  <condition>Cerebral Infarction</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Brush sign</intervention_name>
    <description>presence of a brush sign in MRI image in acute cerebral ischaemia</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient hospitalized between april 2014 and august 2016 for cerebral infarction
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt;18 years old

          -  hospitalized for cerebral infarction

          -  MCA territory

          -  MRI within 24hours

          -  Sequence of magnetic susceptibility (SWAN)

        Exclusion Criteria:

          -  Incomplete cerebral infarct

          -  MRI not possible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>ZUBER Mathieu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>GHPSJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

